Guggenheim analyst Yatin Suneja weighed in on Biogen (NASDAQ: BIIB) saying an initial look at aducanumab (amyloid Ab) briefing docs ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE